





FIG. 1A



XPA.92.019
Binding To Cells With IL2





FIG. 2A

A = 150nM antibody + IL2 added to cells
 B = 150nM antibody added to cells + IL2

XPA.92.041
Binding To Cells With IL2



A = 150nM antibody + IL2 added to cells
 B = 150nM antibody added to cells + IL2

FIG. 2B

XPA.92.042
Binding To Cells With IL2




FIG. 2C

XPA.92.099
Binding To Cells With IL2









FIG. 2D

**FIG. 3A****FIG. 3B**

**FIG. 3C**

**FIG. 4A****FIG. 4B**







FIG. 4C

**FIG. 5A****FIG. 5B**

**FIG. 5C**

NK-92 cells (endogenous human IL-2R $\alpha\beta\gamma$)




FIG. 7A

No Ab	0.0006155
KLH	0.0009353
MAB602	0.8971
19	0.9031
41	1.153
42	1.773
99	0.4634

Human NK cells (only endogenous human IL-R $\beta\gamma$)




FIG. 7B






FIG. 7C

**FIG. 8A****FIG. 8B**




FIG. 8C






FIG. 8D



Vehicle
control




FIG. 9A

IL-2/mAb99




FIG. 9B

anti-PD-1 mAb




FIG. 9C

IL-2/mAb99 +
anti-PD-1 mAb




FIG. 9D

anti-CTLA-4 mAb




FIG. 9E

IL-2/mAb99 +
anti-CTLA-4 mAb




FIG. 9F




FIG. 10A




FIG. 10B




FIG. 11A

FIG. 11B




FIG. 11C




FIG. 11E

FIG. 11D




FIG. 11F

SEQ ID NO:	Name	Sequence
1	XPA.92.019 HV H-CDR1 26-33 H-CDR2 51-58 H-CDR3 97-108	EVQLVESGGG LVQPGRSRL SCASGFTFS YYGMHWVRQA PGKGLEWVAD ISNDGSNKYY ADSVKGRFTI SRDNSKTTLY LQMSLRPED TAVYYCATPY YDSSGLDYWG QGTIVTVSS
2	XPA.92.019 HV	gaagtcgagc tgytggagtc tgggggaggc ttggtccagc ctgggagtc cctgagactc tcctgtgcag cctctgatt caacttcagt tactatygca tgcactygt ccggcagact ccaggcaagg ggcctagagt ggtggcagat atatcaatg atggaagtaa taatatltac gcagactctg tgaaggccg attcaccatc tccagagaca attccaagac cacyctgtat ctgcaaatga acagcctgag acctgagagac acgctgtat attactgtgc gaccoccttac tatgatagta gtgggttga ctactgggc cagggaacc tgytcaccgt ctccca
3	XPA.92.041 HV H-CDR1 26-33 H-CDR2 51-58 H-CDR3 97-106	EVQLVQSGAE VKKPGESLKI SCKGSGYNFD TYWIGVVRQM PGRGLEWMT IYPADSDTRY SPSFQGGVTT SADKSISTAY LQWGLRASD TAMYICARFS SSAYDIWGG TMVTVSS
4	XPA.92.041 HV	gagttccagc tgytaccagtc tygagcagag gtgaaaaagc ccggggagtc tctgaagatt tcctgtgaag gttcttgata caactltgac acgtactgga tcgctygt gcgccagatg cccgggagag gcctggagtg gatgggcacc atctatcctg ctgactctga caccagatat agcccgctct tccaaggcca ggtcacacc tcaagcgaca agtccatcag caccgcctac ctgcagtggg gcagcctgag ggcctcgagc accgccatgt attactgtgc gagtltagc agttctgcct atgacattg gggccaaggg acaatgtca ccgtccttc a
5	XPA.92.042 HV H-CDR1 26-33 H-CDR2 51-58 H-CDR3 97-106	EVQLVQSGTE VKKAGDSLKI SCKGSGYNFD TYWIGVVRQM PGRGLEWMT IYPADSDTRY SPSFQGGVTM SADKSISTAY LQWGLRASD TAMYICARFS SSAYDIWGG TMVTVSS
6	XPA.92.042 HV	gagttccagc tgytaccagtc tygaacagag gtgaaaaagc ccggggagtc tctgaagatt tcctgtgaag gttcttgata caactltgac acgtactgga tcgctygt gcgccagatg cccgggagag gcctggagtg gatgggcacc atctatcctg ctgactctga caccagatat agtcgctcct tccaaggcca ggtcacacc tcaagcgaca agtccatcag caccgcctac ctgcagtggg gcagcctgag ggcctcgagc accgccatgt attactgtgc gagtltcagc agctctgcct atgacattg gggccaaggg acaatgtca ccgtccttc a
7	XPA.92.099 HV H-CDR1 26-33 H-CDR2 51-58 H-CDR3 97-110	QVQLVESGGG LVKPGRSRL SCASGFTFN RYAMSWVRQA PGKGLEWVAM ISFDGNQYY TDSVSGRFTI SRDNSKTTLF LQMSLRITED TAVYYCVRSP AGDWVAYFDY WGQGLIVTVSS

FIG. 12

SEQ ID NO:	Name	Sequence
8	XP.A.92.099 HV	caggtgcagc tgytggagtc tgygggaggc ttggtcaagc ctgggaggtc cctgagctc tcctgtgcag cctctygatt caccttcaat agatatgcca tgagctgggt ccgccaggtc ccagccaagc ggtctagagtg ggtggcgatg atatcatltg atggaggtaa tcaatatlac acagactccg tgaatggccg attcaccatc tccagagaca attccaagac cagctgttt ctgcaaatgg acagcctlgag aactgagcac acggtgtgt attatgtgt gagatccccg gcgggggact ggtltgccta ctttgactac tggggccagc gaacctgtgt cacgctctcc tca
9	XP.A.92.019 LV (lambda) L-CDR1 26-31 L-CDR2 49-51 L-CDR3 88-98	SYELTQPPSV SVSPGQTARI TCSGDALPKR FAIWMYQOKAG QAPVLVIYED NKRPSSGIPET LSGSSSSGTTA TLTISGAQEE DEADYYCYST DNTGGLWVFG GGTKLTVLG
10	XP.A.92.019 LV (lambda)	tcctatgagc tgacacagcc accctcggtg tcagtatccc cagcacaaac ggcacagatc acctgctctg gagatgcatt gccaaaaaga ttgtcttatt gttaccagca gaagccaggc cagggccctg tactgttcatt ctatgagcac aacaaacgac cctccgggat ccctgagaca ctgtctggtc ccaglticagc gacaacggcc acctgacaca tcaatggggc ccagagagag gatgaagctg actactatgt ttactccaca gacaacactg gtgtctctg ggtgttcgyc ggagggacca agctgaccgt cctaggt
11	XP.A.92.041 LV (lambda) L-CDR1 26-31 L-CDR2 49-51 L-CDR3 88-98	SYELTQPPSV SVSPGQTARI TCSGDALPRQ FAIWMYQOKPG QAPVLVIYKD TERPSGIPER FSGSSSSGTTV TLTISGVQAE DEADYYCQSA DSSGTYHVFEG GGTQLTVLG
12	XP.A.92.041 LV (lambda)	tcctatgagc tgacacagcc accctcggtg tcagtgtccc cagcacagac ggcacagatc acctgctctg gagatgcgtt gccaaagcaa ttgtcttatt gttaccagca gaagccaggc cagggccctg tgcgtgtgat atataagac actgagagc cctcaggat ccctgagcga ttctctggtc ccagcticagc gacaacagtc acgtlgacca tcaatggaggt ccagccagaa gaagaggtg actattactg tcaatcagca gaacagcagtg gtactatca cgtgtltgga ggagggaccc agctgaccgt cctaggt
13	XP.A.92.042 LV (lambda) L-CDR1 26-31 L-CDR2 49-51 L-CDR3 88-97	SYELTQPPSV SVSPGQTARI TCSGDALPRK FAIWMYQOKSG QAPVLVIYQD TKRPSSGIPER FSGSSSSGTTV TLTISDVQAE DDADYYCQSA DRSDSYVFEG GGTKLTVLG

FIG. 12 CONT.

SEQ ID NO:	Name	Sequence
14	XPA.92.042 LV (lambda)	tcctatgagc tgcacacagcc accctcggtg tcaqgtgtccc cagcacaaac ggcacagatc accgtctctg gagatgcatc gccaaagaanaa ttigtcttact ggtaccagaca gaagtcaagc cagggccctg tcctggtgat atacaagac actaagagc cctcaggat ccctgagcga ttctctggtc ccagctcagc gacaacagtc acgttgacca tcaqtgacgt ccagycagag gacgacgctg actattatlg tcaqtcagcc gacagaagtg attctlatgt cticgagct gggaccaagc tcaacctcct aggt
15	XPA.92.099 LV (kappa) L-CDR1 27-32 L-CDR2 50-52 L-CDR3 89-98	DIQMTQSPSS ISASIGDRVIT IPCQASEDIS NHLSWYQKP GKAPKPLIFD ASDLETGVPS RFSGSGSGTD FALTISSLRP DDFATYYCHQ YHDYPSYTFG HGTKLEIKR
16	XPA.92.099 LV (kappa)	gacatccaga tgcaccagtc tccttcctcc ctgtctgctt ctatlggaga cagagtcacc atccctcgcc aggcgagtga ggcacatagtt aatcatlttaa gttggtatca gcagaacacca gggaagcccc ctaaacccct gatcttcgat gcatccgatt tgyaacagc gttcccatca aggttcagtg gaagtgtatc tgggacagat ttgtctctca ccacagcag cctgcgcct gatgatlttg caactlatla ctgcccacag tatcatgatlt atccctcgta caattltgyc cacgggacca agctggagat caaacgt
17	XPA.92.019 HV H-CDR1	GFTEFSYYG
18	XPA.92.019 HV H-CDR2	ISNDGSNK
19	XPA.92.019 HV H-CDR3	ATPYDSSGLDY
20	XPA.92.041 HV H-CDR1	GYNFDTYW
21	XPA.92.041 HV H-CDR2	IYPADSDT
22	XPA.92.041 HV H-CDR3	ARFSSSAYDI
23	XPA.92.042 HV H-CDR1	GYNFDTYW
24	XPA.92.042 HV H-CDR2	IYPADSDT

FIG. 12 CONT.

SEQ ID NO:	Name	Sequence
25	XP.A.92.042 HV H-CDR3	SSAYDIARFS
26	XP.A.92.099 HV H-CDR1	GFTFNRYA
27	XP.A.92.099 HV H-CDR2	ISFDGNQ
28	XP.A.92.099 HV H-CDR3	VRSFAGDWVAYFDY
29	XP.A.92.019 LV (lambda) L-CDR1	ALPKRF
30	XP.A.92.019 LV (lambda) L-CDR2	EDN
31	XP.A.92.019 LV (lambda) L-CDR3	YSTDNTGGLWV
32	XP.A.92.041 LV (lambda) L-CDR1	ALPRQF
33	XP.A.92.041 LV (lambda) L-CDR2	KDT
34	XP.A.92.041 LV (lambda) L-CDR3	DSSGTYHQA
35	XP.A.92.042 LV (lambda) L-CDR1	ALPKRF
36	XP.A.92.042 LV (lambda)	QDT

FIG. 12 CONT.

SEQ ID NO:	Name	Sequence
	L-CDR2	
37	XPA.92.042 LV (lambda) L-CDR3	QSAADRSDSYV
38	XPA.92.099 LV (kappa) L-CDR1	EDISNH
39	XPA.92.099 LV (kappa) L-CDR2	DAS
40	XPA.92.099 LV (kappa) L-CDR3	HQYHDPSTT

HV= Heavy Chain Variable Region
LV= Light Chain Variable Region

FIG. 12 CONT.




FIG. 13A








FIG. 13B



Sample


FIG. 13C

**FIG. 14A****FIG. 14B**




Sample

FIG. 14C

Donor 603

- No Antibody
- XPA.92.019
- ◇ XPA.92.042
- △ XPA.92.099
- MAB602

	EC50
No Antibody	1.695
XPA.92.019	11.32
XPA.92.042	11.8
XPA.92.099	8.264
MAB602	6.519

FIG. 15A**Donor 625**

- No Antibody
- XPA.92.019
- ◇ XPA.92.042
- △ XPA.92.099
- MAB602

	EC50
No Antibody	
XPA.92.019	8.09
XPA.92.042	6.864
XPA.92.099	3.645
MAB602	4.146

FIG. 15B



**FIG. 16****FIG. 17**

FIG. 18